Kymera Therapeutics, a clinical-stage biopharmaceutical company, has released updated clinical data from the phase 1 trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413. The new data shows that both programs continue to demonstrate substantial target knockdown in ongoing clinical trials with no dose limiting toxicities observed. Kymera is developing these drugs to target protein degradation for hematological malignancies and solid tumors. The company will share more data on additional KT-333 and KT-413 patient cohorts next week during the International Conference on Malignant Lymphoma (ICML) meeting.
Keywords: Kymera Therapeutics, clinical data, STAT3 Degrader KT-333, IRAKIMiD Degrader KT-413, protein degradation.
Kymera Therapeutics Inc. announced that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials.
The Phase 1 clinical trial of KT-333 is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of KT-333 dosed weekly in adult patients with relapsed and/or refractory lymph